ReviewNature immunology2015
Antiviral B cell and T cell immunity in the lungs.
Review in Nature immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 148 citations in OpenAlex.
- Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection.The Journal of clinical investigation · 2020Trial
- Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026Review
- Multi-Epitope mRNA Vaccine TargetingBioinformatics and biology insights · 2026Article
- Dietary saturated fatty acids promote lung myeloid cell inflammasome activation and IL-1β-mediated inflammation in mice and humans.Science translational medicine · 2025Article
- The intricate interplay among microbiota, mucosal immunity, and viral infection in the respiratory tract.Journal of translational medicine · 2025Review
- Recent advances in TAM mechanisms in lung diseases.Journal of translational medicine · 2025Review
- Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications.Vaccines · 2025Review
- Harnessing Epigenetics: Innovative Approaches in Diagnosing and Combating Viral Acute Respiratory Infections.Pathogens (Basel, Switzerland) · 2025Review
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.The Journal of infectious diseases · 2024Article
- Single-cell analysis reveals lasting immunological consequences of influenza infection and respiratory immunization in the pig lung.PLoS pathogens · 2024Article
- Immune Response to Respiratory Viral Infections.International journal of molecular sciences · 2024Review
- Vascular endothelial-derived SPARCL1 exacerbates viral pneumonia through pro-inflammatory macrophage activation.Nature communications · 2024Article
- Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults.Deutsches Arzteblatt international · 2024Review
- Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date.Paediatric drugs · 2024Article
- Causal Involvement of Immune Cells in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2024Article
- Predicting airway immune responses and protection from immune parameters in blood following immunization in a pig influenza model.Frontiers in immunology · 2024Article
- In Silico design of a multi-epitope vaccine for Human Parechovirus: Integrating immunoinformatics and computational techniques.PloS one · 2024Article
- Lung cDC1 and cDC2 dendritic cells priming naive CD8Cell reports · 2023Article
- Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Respiratory viruses are frequent causes of repeated common colds, bronchitis and pneumonia, which often occur unpredictably as epidemics and pandemics. Despite those decimating effects on health and decades of intensive research, treatments remain largely supportive. The only commonly available vaccines are against influenza virus, and even these need improvement. The lung shares some features with other mucosal sites, but preservation of its especially delicate anatomical structures necessitates a fine balance of pro- and anti-inflammatory responses; well-timed, appropriately placed and tightly regulated T cell and B cell responses are essential for protection from infection and limitation of symptoms, whereas poorly regulated inflammation contributes to tissue damage and disease. Recent advances in understanding adaptive immunity should facilitate vaccine development and reduce the global effect of respiratory viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.